KINGWORLD MEDICINES GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.62 HKD | +8.77% |
|
+6.90% | -1.59% |
| 23/04 | Kingworld Medicines Posts 68% Jump in 2023 Profit | MT |
| 27/03 | Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 535.7 | 489.6 | 392.9 | 385.5 | 467.3 | 356.5 |
| Enterprise Value (EV) 1 | 696.6 | 592.5 | 437.3 | 426 | 501.8 | 516.8 |
| P/E ratio | 13.1 x | 11.2 x | 33.1 x | 12.4 x | 20 x | 8.89 x |
| Yield | 2.3% | 2.66% | 0.87% | 3.15% | 2.9% | 5.34% |
| Capitalization / Revenue | 0.5 x | 0.5 x | 0.53 x | 0.45 x | 0.49 x | 0.33 x |
| EV / Revenue | 0.65 x | 0.61 x | 0.59 x | 0.5 x | 0.52 x | 0.48 x |
| EV / EBITDA | 7.68 x | 6.29 x | 4.8 x | 4.42 x | 4.67 x | 5.84 x |
| EV / FCF | 13.2 x | 5.34 x | 4.09 x | 39.9 x | 5.74 x | -7.96 x |
| FCF Yield | 7.56% | 18.7% | 24.5% | 2.5% | 17.4% | -12.6% |
| Price to Book | 0.95 x | 0.81 x | 0.66 x | 0.62 x | 0.76 x | 0.55 x |
| Nbr of stocks (in thousands) | 6,22,500 | 6,22,500 | 6,22,500 | 6,22,500 | 6,22,500 | 6,22,500 |
| Reference price 2 | 0.8605 | 0.7864 | 0.6312 | 0.6193 | 0.7507 | 0.5726 |
| Announcement Date | 23/04/19 | 23/04/20 | 23/04/21 | 25/04/22 | 21/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,079 | 977.9 | 745.4 | 847.4 | 957.7 | 1,079 |
| EBITDA 1 | 90.73 | 94.24 | 91.16 | 96.46 | 107.4 | 88.52 |
| EBIT 1 | 63.3 | 66.41 | 66.84 | 71.24 | 80.34 | 78.68 |
| Operating Margin | 5.87% | 6.79% | 8.97% | 8.41% | 8.39% | 7.29% |
| Earnings before Tax (EBT) 1 | 70.38 | 69.81 | 70.89 | 69.43 | 67.58 | 93.89 |
| Net income 1 | 41 | 43.43 | 11.72 | 30.32 | 22.74 | 38.1 |
| Net margin | 3.8% | 4.44% | 1.57% | 3.58% | 2.37% | 3.53% |
| EPS 2 | 0.0659 | 0.0700 | 0.0191 | 0.0500 | 0.0375 | 0.0644 |
| Free Cash Flow 1 | 52.63 | 111 | 107 | 10.66 | 87.37 | -64.91 |
| FCF margin | 4.88% | 11.35% | 14.35% | 1.26% | 9.12% | -6.02% |
| FCF Conversion (EBITDA) | 58.01% | 117.82% | 117.37% | 11.06% | 81.36% | - |
| FCF Conversion (Net income) | 128.35% | 255.66% | 913.23% | 35.18% | 384.2% | - |
| Dividend per Share 2 | 0.0198 | 0.0209 | 0.005500 | 0.0195 | 0.0218 | 0.0306 |
| Announcement Date | 23/04/19 | 23/04/20 | 23/04/21 | 25/04/22 | 21/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 161 | 103 | 44.3 | 40.6 | 34.5 | 160 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.773 x | 1.093 x | 0.4861 x | 0.4204 x | 0.3213 x | 1.812 x |
| Free Cash Flow 1 | 52.6 | 111 | 107 | 10.7 | 87.4 | -64.9 |
| ROE (net income / shareholders' equity) | 8.09% | 7.67% | 7.53% | 7.32% | 6.16% | 8.84% |
| ROA (Net income/ Total Assets) | 3.01% | 3.22% | 3.29% | 3.61% | 4.05% | 3.78% |
| Assets 1 | 1,363 | 1,348 | 355.6 | 840.7 | 561 | 1,008 |
| Book Value Per Share 2 | 0.9100 | 0.9700 | 0.9500 | 0.9900 | 0.9900 | 1.040 |
| Cash Flow per Share 2 | 0.2600 | 0.1800 | 0.4000 | 0.3000 | 0.3900 | 0.2900 |
| Capex 1 | 11.9 | 8.8 | 9.93 | 58.3 | 93.5 | 106 |
| Capex / Sales | 1.1% | 0.9% | 1.33% | 6.88% | 9.76% | 9.78% |
| Announcement Date | 23/04/19 | 23/04/20 | 23/04/21 | 25/04/22 | 21/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.59% | 43.28M | |
| +20.04% | 72.24B | |
| +7.33% | 8.92B | |
| +10.34% | 8.58B | |
| -19.68% | 8.07B | |
| +14.10% | 5.24B | |
| +14.69% | 4.24B | |
| -1.04% | 4.15B | |
| -2.54% | 3.92B | |
| +25.30% | 3.75B |
- Stock Market
- Equities
- 1110 Stock
- Financials Kingworld Medicines Group Limited
